Subscribe to RSS
Triarylpyrazole Derivatives as Potent Cytotoxic Agents; Synthesis and Bioactivity Evaluation “Pyrazole Derivatives as Anticancer Agent”Funding: This work was financially supported by The National Institute for Medical Research Development (NIMAD), GN: 958948.
Background During the last recent years, several anti-cancer agents were introduced for the treatment of diverse kinds of cancer. Despite their potential in the treatment of cancer, drug resistance and adverse toxicity such as peripheral neuropathy are some of the negative criteria of anti-cancer agents and for this reason, the design and synthesis of new anti-cancer agents are important.
Objective Design, synthesis, and anticancer activity evaluation of some pyrazole derivatives.
Methods A series of Target compounds were prepared using multistep synthesis. Their cytotoxic activity against three different human cancer cell lines namely human colon carcinoma cells (HT-29), epithelial carcinoma cells (U-87MG), pancreatic cancerous cells (Panc-1) as well as AGO1522 normal cell line using in vitro 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay was investigated.
Results 1,3-Diaryl-5-(3,4,5-trimethoxyphenyl)-4,5-dihydro-1H-pyrazole and 1,3-Diaryl-5-(3,4,5-trimethoxyphenyl)- 1H-pyrazole were synthesized in good yields and their structure and purity were confirmed using 1H-NMR, 13C-NMR, and elemental analysis. Generally, the synthesized scaffolds exhibited good cytotoxicity against cancerous cell lines in comparison to the reference standard, paclitaxel. Compounds 3a and 3c, in Annexin V/ PI staining assay, exerted remarkable activity in apoptosis induction in HT-29 cell lines. Both of them also led to cell cycle arrest in the sub-G1 phase which is inconsistent with the results of apoptosis assay.
Conclusion Concerning obtained results, it is interesting to synthesis more pyrazole derivatives as anticancer agents.
Received: 11 February 2021
Accepted: 30 April 2021
19 May 2021 (online)
© 2021. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
- 1 Elmore S. Apoptosis: A Review of Programmed Cell Death. Toxicol Pathol 2007; 35: 495-516
- 2 Roshal M, Zhu Y, Planelles V. Apoptosis in AIDS. Apoptosis 2001; 6: 103-116
- 3 Wong RSY. Apoptosis in cancer: From pathogenesis to treatment. J. Exp. Clin. Cancer Res 2011; 30: 87-100
- 4 Jo WS, Jeong MH, Jin YH. et al. Loss of mitochondrial membrane potential and caspase activation enhance apoptosis in irradiated K562 cells treated with herbimycin A. Int J Radiat Biol 2005; 81: 531-543
- 5 Brancolini C, Lazarevic D, Rodriguez J. et al. Dismantling Cell–Cell Contacts during Apoptosis Is Coupled to a Caspase-dependent Proteolytic Cleavage of β-Catenin. J Cell Biol 1997; 139: 759-771
- 6 Taylor RC, Cullen SP, Martin SJ. Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol 2008; 9: 231-241
- 7 Baig S, Seevasant I, Mohamad J. et al. Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?. Cell Death Dis 2016; 7: e2058
- 8 Moudi M, Go R, Yien CYS. et al. Vinca Alkaloids. Int J Prev Med 2013; 4: 1231-1235
- 9 Ganansia-Leymarie V, Bischoff P, Bergerat JP. et al. Signal transduction pathways of taxanes-induced apoptosis. Curr Med Chem Anticancer Agents 2003; 3: 291-306
- 10 Sackett DL. Podophyllotoxin, steganacin and combretastatin: Natural products that bind at the colchicine site of tubulin. Pharmacol. Ther 1993; 59: 163-228
- 11 Lin CM, Ho HH, Pettit GR. et al. Antimitotic natural products combretastatin A-4 and combretastatin A-2: Studies on the mechanism of their inhibition of the binding of colchicine to tubulin. Biochemistry 1989; 28: 6984-6991
- 12 Theeramunkong S, Caldarelli A, Massarotti A. et al. Regioselective Suzuki coupling of dihaloheteroaromatic compounds as a rapid strategy to synthesize potent rigid combretastatin analogues. J Med Chem 2011; 54: 4977-4986
- 13 Biersack B, Muthukumar Y, Schobert R. et al. Cytotoxic and antivascular 1-methyl-4-(3-fluoro-4-methoxyphenyl)-5-(halophenyl)-imidazoles. Bioorg Med Chem Lett 2011; 21: 6270-6273
- 14 Kaffy J, Pontikis R, Carrez D. et al. Isoxazole-type derivatives related to combretastatin A-4, synthesis and biological evaluation. Bioorg Med Chem 2006; 14: 4067-4077
- 15 Wu M, Sun Q, Yang C. et al. Synthesis and activity of Combretastatin A-4 analogues: 1,2,3-thiadiazoles as potent antitumor agents. Bioorg Med Chem Lett 2007; 17: 869-873
- 16 Romagnoli R, Baraldi PG, Cruz-Lopez O. et al. Synthesis and Antitumor Activity of 1,5-Disubstituted 1,2,4-Triazoles as Cis-Restricted Combretastatin Analogues. J med chem 2010; 53: 4248-4258
- 17 Romagnoli R, Baraldi PG, Salvador MK. et al. Synthesis and evaluation of 1,5-disubstituted tetrazoles as rigid analogues of combretastatin A-4 with potent antiproliferative and antitumor activity. J Med Chem 2012; 55: 475-488
- 18 Assadieskandar A, Amini M, Ostad SN. et al. Design, synthesis, cytotoxic evaluation and tubulin inhibitory activity of 4-aryl-5-(3,4,5-trimethoxyphenyl)-2-alkylthio-1H-imidazole derivatives. Bioorg Med Chem 2013; 21: 2703-2709
- 19 Salehi M, Amini M, Ostad SN. et al. Synthesis, cytotoxic evaluation and molecular docking study of 2-alkylthio-4-(2,3,4-trimethoxyphenyl)-5-aryl-thiazoles as tubulin polymerization inhibitors. Bioorg Med Chem 2013; 21: 7648-7654
- 20 Saravani F, Saeedian Moghadam E, Salehabadi H. et al. Synthesis, anti-proliferative evaluation, and molecular docking studies of 3-(alkylthio)-5,6-diaryl-1,2,4-triazines as tubulin polymerization inhibitors. Lett Drug Des Discov 2018; 16: 1194-1201
- 21 Saeedian Moghadam E, Saravani F, Ostad SN. et al. Design, synthesis and cytotoxicity evaluation of indibulin analogs. Heterocycl. Commun 2018; 24: 211-218
- 22 Saeedian Moghadam E, Saravani F, Ostad SN. et al. Design, Synthesis and Anticancer Evaluation of Novel Series of Indibulin Analogues. Med Chem 2019; 15: 231-239
- 23 Supuran CT, Popescu A, Ilisiu M. et al. Carbonic anhydrase inhibitors. Part 36. Inhibition of isozymes I and II with Schiff bases derived from chalkones and aromatic/heterocyclic sulfonamides. Eur J Med Chem 1996; 31: 439-447